Cosmos Health Inc. (COSM)
USD 0.45
(-2.91%)
USD 0.45
(-2.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 8.59 Million USD | 198.47% |
| 2022 | -8.72 Million USD | -132.51% |
| 2021 | 26.83 Million USD | -14.57% |
| 2020 | 31.41 Million USD | 63.21% |
| 2019 | 19.24 Million USD | 22.5% |
| 2018 | 15.71 Million USD | 67.24% |
| 2017 | 9.39 Million USD | 278.48% |
| 2016 | 2.48 Million USD | 920.02% |
| 2015 | 243.37 Thousand USD | 103.65% |
| 2014 | -6.67 Million USD | -854.46% |
| 2013 | -699.48 Thousand USD | 0.0% |
| 2012 | - USD | 100.0% |
| 2011 | -15.23 Thousand USD | -3142.13% |
| 2010 | -470.00 USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 10.53 Million USD | 22.64% |
| 2024 Q2 | 11.46 Million USD | 8.86% |
| 2023 FY | 8.59 Million USD | 198.47% |
| 2023 Q1 | -2.27 Million USD | 73.92% |
| 2023 Q4 | 8.59 Million USD | 1.96% |
| 2023 Q2 | 7.22 Million USD | 417.68% |
| 2023 Q3 | 8.42 Million USD | 16.57% |
| 2022 Q3 | 22.81 Million USD | 2.95% |
| 2022 FY | -8.72 Million USD | -132.51% |
| 2022 Q1 | 21.15 Million USD | -21.18% |
| 2022 Q2 | 22.16 Million USD | 4.77% |
| 2022 Q4 | -8.72 Million USD | -138.24% |
| 2021 Q1 | 28.19 Million USD | -10.25% |
| 2021 FY | 26.83 Million USD | -14.57% |
| 2021 Q2 | 26.99 Million USD | -4.27% |
| 2021 Q3 | 26.07 Million USD | -3.38% |
| 2021 Q4 | 26.83 Million USD | 2.91% |
| 2020 Q1 | 20.54 Million USD | 6.75% |
| 2020 FY | 31.41 Million USD | 63.21% |
| 2020 Q2 | 25.13 Million USD | 22.34% |
| 2020 Q3 | 29.75 Million USD | 18.36% |
| 2020 Q4 | 31.41 Million USD | 5.59% |
| 2019 Q4 | 19.24 Million USD | 9.62% |
| 2019 FY | 19.24 Million USD | 22.5% |
| 2019 Q1 | 15.62 Million USD | 10.33% |
| 2019 Q2 | 16.94 Million USD | 8.46% |
| 2019 Q3 | 17.55 Million USD | 3.64% |
| 2018 Q1 | 12.37 Million USD | 31.72% |
| 2018 Q4 | 14.15 Million USD | 31.61% |
| 2018 Q3 | 10.75 Million USD | 1.79% |
| 2018 Q2 | 10.56 Million USD | -14.6% |
| 2018 FY | 15.71 Million USD | 67.24% |
| 2017 FY | 9.39 Million USD | 278.48% |
| 2017 Q4 | 9.39 Million USD | 9.28% |
| 2017 Q3 | 8.59 Million USD | 45.85% |
| 2017 Q2 | 5.89 Million USD | 87.04% |
| 2017 Q1 | 3.15 Million USD | 26.96% |
| 2016 Q4 | 2.48 Million USD | 50.93% |
| 2016 FY | 2.48 Million USD | 920.02% |
| 2016 Q3 | 1.64 Million USD | 401.35% |
| 2016 Q2 | 328.07 Thousand USD | 60.17% |
| 2016 Q1 | 204.82 Thousand USD | -15.84% |
| 2015 Q1 | -5.76 Million USD | 13.61% |
| 2015 FY | 243.37 Thousand USD | 103.65% |
| 2015 Q4 | 243.37 Thousand USD | -43.96% |
| 2015 Q3 | 434.26 Thousand USD | 107.49% |
| 2015 Q2 | -5.79 Million USD | -0.53% |
| 2014 FY | -6.67 Million USD | -854.46% |
| 2014 Q4 | -6.67 Million USD | -8385.89% |
| 2014 Q3 | 80.57 Thousand USD | 111.92% |
| 2014 Q2 | -676.02 Thousand USD | 17.54% |
| 2014 Q1 | -819.78 Thousand USD | -17.2% |
| 2013 Q3 | -351.21 Thousand USD | -1764.61% |
| 2013 FY | -699.48 Thousand USD | 0.0% |
| 2013 Q4 | -699.48 Thousand USD | -99.16% |
| 2013 Q1 | 118.85 Thousand USD | -22.46% |
| 2013 Q2 | -18.83 Thousand USD | -115.85% |
| 2012 Q3 | 123.75 Thousand USD | 309495.0% |
| 2012 Q4 | 153.28 Thousand USD | 23.86% |
| 2012 FY | - USD | 100.0% |
| 2012 Q1 | 14.78 Thousand USD | 20.14% |
| 2012 Q2 | -40.00 USD | -100.27% |
| 2011 Q4 | 12.3 Thousand USD | 753.61% |
| 2011 Q1 | -56.44 Thousand USD | -479.46% |
| 2011 Q2 | -15.23 Thousand USD | 73.01% |
| 2011 Q3 | 1442.00 USD | 109.46% |
| 2011 FY | -15.23 Thousand USD | -3142.13% |
| 2010 Q3 | 15.82 Thousand USD | 3465.96% |
| 2010 Q2 | -470.00 USD | -104.39% |
| 2010 Q1 | 10.7 Thousand USD | 855.89% |
| 2010 Q4 | 14.87 Thousand USD | -5.97% |
| 2010 FY | -470.00 USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | 1120.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 90.881% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 88.538% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 98.027% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 204.593% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 98.127% |
| Cronos Group Inc. | -663.32 Million USD | 101.295% |
| Incannex Healthcare Limited | -5.48 Million USD | 256.623% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 158.954% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 92.953% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 396.087% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 154.947% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 154.947% |
| SCYNEXIS, Inc. | -19.35 Million USD | 144.397% |
| Safety Shot Inc | -2.28 Million USD | 476.066% |
| Theratechnologies Inc. | 24.87 Million USD | 65.459% |
| Alpha Teknova, Inc. | 1.97 Million USD | -335.195% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -4256.169% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 98.015% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 440.903% |
| Dynavax Technologies Corporation | 106.63 Million USD | 91.944% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 98.622% |
| Radius Health, Inc. | 359.28 Million USD | 97.609% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 191.103% |
| Alvotech | 1.06 Billion USD | 99.193% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 106.566% |
| SIGA Technologies, Inc. | -148.68 Million USD | 105.778% |
| Shineco, Inc. | 29.29 Million USD | 70.67% |
| Silver Spike Investment Corp. | -32.61 Million USD | 126.343% |
| Journey Medical Corporation | -9.7 Million USD | 188.482% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 269.765% |
| Embecta Corp. | 1.31 Billion USD | 99.345% |
| Harrow Health, Inc. | 116.41 Million USD | 92.621% |
| Procaps Group, S.A. | 242.93 Million USD | 96.464% |
| Biofrontera Inc. | 4.05 Million USD | -111.804% |
| DURECT Corporation | -7.65 Million USD | 212.239% |
| PainReform Ltd. | -7.95 Million USD | 208.06% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 125.623% |
| OptiNose, Inc. | 58.06 Million USD | 85.205% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 265.652% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 42.778% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -7939.339% |
| ProPhase Labs, Inc. | 19.23 Million USD | 55.329% |
| Phibro Animal Health Corporation | 454.84 Million USD | 98.111% |
| Procaps Group S.A. | 242.93 Million USD | 96.464% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -133.571% |
| Viatris Inc. | 17.13 Billion USD | 99.95% |
| Rockwell Medical, Inc. | 4.45 Million USD | -92.791% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 276.148% |
| Tilray Brands, Inc. | 158.97 Million USD | 94.596% |
| PetIQ, Inc. | 351.93 Million USD | 97.559% |
| Talphera, Inc. | -5.72 Million USD | 250.162% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 95.155% |
| Alimera Sciences, Inc. | 55.3 Million USD | 84.468% |
| Assertio Holdings, Inc. | -32.52 Million USD | 126.41% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 677.056% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -103.717% |
| Hempacco Co., Inc. | 13.61 Million USD | 36.901% |
| Alvotech | 1.06 Billion USD | 99.193% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 108.883% |
| Kamada Ltd. | -46.43 Million USD | 118.502% |
| Currenc Group, Inc. | -16.57 Million USD | 151.835% |
| Indivior PLC | -33.95 Million USD | 125.303% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -3196.859% |
| Flora Growth Corp. | -713 Thousand USD | 1304.875% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 204.593% |
| Evolus, Inc. | 63.7 Million USD | 86.515% |
| HUTCHMED (China) Limited | -197.45 Million USD | 104.351% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 98.207% |
| Akanda Corp. | 3.9 Million USD | -119.999% |